Intervention

L-NMMA

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 9 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials9

Recruiting1

Common conditions17

Lead sponsors shown6

Clinical trials

9 shown

Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)NCT05660083 · 2023-01-12

RECRUITING

Phase Ib of L-NMMA and PembrolizumabNCT03236935 · 2018-08-27

COMPLETED

L-NMMA Plus Taxane Chemotherapy in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer PatientsNCT02834403 · 2016-11-01

COMPLETED

SAFEGUARD: Pleiotropic Effects of Incretin Based TherapiesNCT01744236 · 2013-04-01

COMPLETED

Effect of DPP4 Inhibition on Growth Hormone SecretionNCT01701973 · 2013-01-01

COMPLETED

Pathophysiology of Cardiometabolic Risk Factors in African AmericansNCT01122407 · 2010-01-01

COMPLETED

Sildenafil to Treat HIV-Associated Pulmonary HypertensionNCT00327080 · 2006-05-12

TERMINATED

The Effect of Lopinavir/Ritonavir on Endothelial FunctionNCT00076414 · 2004-01-01

COMPLETED

Nitric Oxide and the Autonomic Nervous SystemNCT00178919 · 2002-08-01

COMPLETED

Common conditions

Hypertension2 Obesity2 Classical Hodgkin Lymphoma1 DNA Repair-Deficiency Disorders1 Head and Neck Squamous Cell Carcinoma1 Healthy1 HER2-negative Breast Cancer1 HIV1 Malignant Melanoma1 Metaplastic Breast Carcinoma1 Metastatic Breast Cancer1 Metastatic Triple Negative Breast Cancer1 Non-Small Cell Lung Cancer1 Pure Autonomic Failure1 TNBC - Triple-Negative Breast Cancer1 Type 2 Diabetes1 Urothelial Carcinoma Bladder1

Leading sponsors

The Methodist Hospital Research Institute 3 Vanderbilt University 2 Amsterdam UMC, location VUmc 1 National Heart, Lung, and Blood Institute (NHLBI) 1 National Institutes of Health Clinical Center (CC) 1 Vanderbilt University Medical Center 1

Trial status mix

COMPLETED7

RECRUITING1

TERMINATED1

Phase mix

PHASE15

PHASE22

PHASE42

NA1

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.